DSpace Repository

Epidemiology of Plasmodium vivax Malaria in Peru

Show simple item record

dc.contributor.author Rosas-Aguirre, Angel
dc.contributor.author Gamboa, Dionicia
dc.contributor.author Manrique, Paulo
dc.contributor.author Conn, Jan-E.
dc.contributor.author Moreno, Marta
dc.contributor.author Lescano, Andres-G.
dc.contributor.author Sanchez, Juan-F.
dc.contributor.author Rodriguez, Hugo
dc.contributor.author Silva, Hermann
dc.contributor.author Llanos-Cuentas, Alejandro
dc.contributor.author Vinetz, Joseph-M.
dc.date.accessioned 2019-02-06T14:45:58Z
dc.date.available 2019-02-06T14:45:58Z
dc.date.issued 2016
dc.identifier.uri https://hdl.handle.net/20.500.12866/5153
dc.description.abstract Malaria in Peru, dominated by Plasmodium vivax, remains a public health problem. The 1990s saw newly epidemic malaria emerge, primarily in the Loreto Department in the Amazon region, including areas near to Iquitos, the capital city, but sporadic malaria transmission also occurred in the 1990s–2000s in both north-coastal Peru and the gold mining regions of southeastern Peru. Although a Global Fund-supported intervention (PAMAFRO, 2005–2010) was temporally associated with a decrease of malaria transmission, from 2012 to the present, both P. vivax and Plasmodium falciparum malaria cases have rapidly increased. The Peruvian Ministry of Health continues to provide artemesinin-based combination therapy for microscopy-confirmed cases of P. falciparum and chloroquine–primaquine for P. vivax. Malaria transmission continues in remote areas nonetheless, where the mobility of humans and parasites facilitates continued reintroduction outside of ongoing surveillance activities, which is critical to address for future malaria control and elimination efforts. Ongoing P. vivax research gaps in Peru include the following: identification of asymptomatic parasitemics, quantification of the contribution of patent and subpatent parasitemics to mosquito transmission, diagnosis of nonparasitemic hypnozoite carriers, and implementation of surveillance for potential emergence of chloroquine- and 8-aminoquinoline-resistant P. vivax. Clinical trials of tafenoquine in Peru have been promising, and glucose-6-phosphate dehydrogenase deficiency in the region has not been observed to be a limitation to its use. Larger-scale challenges for P. vivax (and malaria in general) in Peru include logistical difficulties in accessing remote riverine populations, consequences of government policy and poverty trends, and obtaining international funding for malaria control and elimination. en_US
dc.language.iso eng
dc.publisher American Society of Tropical Medicine and Hygiene
dc.relation.ispartof urn:issn:1476-1645
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Plasmodium vivax/genetics en_US
dc.subject Animals en_US
dc.subject Anopheles/parasitology/physiology en_US
dc.subject Antimalarials/administration & dosage/therapeutic use en_US
dc.subject Endemic Diseases en_US
dc.subject Humans en_US
dc.subject Incidence en_US
dc.subject Insect Vectors en_US
dc.subject Malaria, Vivax/epidemiology en_US
dc.subject Peru/epidemiology en_US
dc.subject Pharmacogenomic Variants en_US
dc.subject Public Health en_US
dc.subject Time Factors en_US
dc.title Epidemiology of Plasmodium vivax Malaria in Peru en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.4269/ajtmh.16-0268
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.06 es_PE
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.06


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics